Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
  • #4644


    What can you tell us about the use of Shingrix in patients receiving immunotherapy? I know it probably hasn’t been studied yet in this setting, but do you suspect that it would be safer than Zostavax in this setting (theoretically)?

    Expert Nurse
    Avatar photoKrista Rubin

      HI Lisa- you ask an excellent question.

      – Shingrix is non-live, recombinant vaccine just recently approved for prevention of zoster.
      – Zostavax is a live, attenuated vaccine approved for prevention of zoster.

      Given the recommendation to avoid live vaccines while on immunotherapy, Shingrix would be the better of the two choices. Agreed- we do not have data regarding safety of use in the setting of immune therapy, specifically immune checkpoint inhibitors, but theoretically…..

      This may be an ideal option for patients at risk; and importantly, prevention of zoster prevents associated post-herpetic neuralgia—this is debilitating for some individuals.

      Thanks for posing this question Lisa.

    Viewing 2 posts - 1 through 2 (of 2 total)
    • You must be logged in to reply to this topic.